MESOBLAST LIMITED (MSB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MSB

MSB - MESOBLAST LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -2.15
Index: ASX200 | ASX300 | ALL-ORDS

Mesoblast is a Melbourne-headquartered medical research company investigating stem cell treatments and allogenic cellular medicines. The company was founded and listed in 2004.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.36

07 Aug
2025

-0.070

OPEN

$2.40

-2.88%

HIGH

$2.42

3,518,224

LOW

$2.34

TARGET
$3.50 48.3% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MSB: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) - 9.1 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-13.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx9.0 M
Book Value Per Share xxxxxxxxxxxxxxx63.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-85.1 M
Net Profit Margin xxxxxxxxxxxxxxx-1,490.27 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-18.22 %
Return on Invested Capital xxxxxxxxxxxxxxx-15.03 %
Return on Assets xxxxxxxxxxxxxxx-13.37 %
Return on Equity xxxxxxxxxxxxxxx-18.22 %
Return on Total Capital xxxxxxxxxxxxxxx-9.83 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-85.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx25 M
Long Term Debt xxxxxxxxxxxxxxx153 M
Total Debt xxxxxxxxxxxxxxx178 M
Goodwill - Gross xxxxxxxxxxxxxxx201 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx94 M
Price To Book Value xxxxxxxxxxxxxxx1.57

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx5.61 %
Cost of Goods Sold xxxxxxxxxxxxxxx24 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx75 M
Research & Development xxxxxxxxxxxxxxx39 M
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

21/07/2025

1

Speculative Buy

$3.50

48.31%

Mesoblast's quarterly update showed cash flow of US$13.2m from Ryoncil's gross sales, which met Bell Potter's expectations, including sales to the distributor.

The broker notes operating cash burn stood at -US$16.6m, including US$1.1m in customer receipts, and is expected to decline as revenue growth improves and receivables are collected in the next few weeks.

Cash at quarter end was US$161m, with net cash of around US$40m. Speculative Buy retained. Target lifts to $3.50 from $3.40. No changes to the analyst's EPS estimates.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -9.12 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -8.66 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

07/08/2025

1

Initiation of coverage with Buy

$2.97

25.85%

Canaccord Genuity initiates coverage of Mesoblast with a Buy rating and $2.97 target price and highlights the company specialises in cell therapy treatments in allogeneic (from one donor versus a matched donor or recipient) off-the-shelf therapies which target severe inflammatory diseases.

Ryoncil is the first-ever approved allogeneic stem cell therapy, which treats paediatric Steroid-Refractory aGvHD, a life-threatening complication that can occur after an allogeneic bone marrow or stem cell transplant.

Post its launch, Mesoblast announced sales of US$13.2m units in 4Q25, with onboarding of 25 hospitals as at June 30, which the analyst views as very "solid".

Other assets in the pipeline are Revascor for ischaemic heart failure with a US$19.2bn total addressable market, and MPC-06-ID with a US$2.6bn total addressable market.

The report highlights both assets have displayed supportive clinical data.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -9.43 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -6.96 cents.
Access Extra Coverage Research History >

MSB STOCK CHART

FNArena News on MSB

1
Australian Broker Call *Extra* Edition – Aug 07, 2025

Aug 07 2025 - Daily Market Reports
2
July In Review: Rotation Into A New All-Time High

Aug 06 2025 - Australia
3
FNArena Corporate Results Monitor – 28-02-2025

Feb 28 2025 - Australia
4
Next Week At A Glance – 20-24 Jan 2025

Jan 17 2025 - Weekly Reports
5
Next Week At A Glance – 7-11 Oct 2024

Oct 04 2024 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
2
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
3
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
4
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
5
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
6
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
7
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
8
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
9
CSL Shares Breaking Free

Jul 23 2024 - Technicals
10
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps